This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Allergan Meets EPS Estimates

Allergan (AGN - Get Report) reported Tuesday that it met earnings expectations and beat on revenue in the third quarter.

The Irvine, Calif.-based company earned 50 cents a share from continuing operations vs. 35 cents a share in the year-ago quarter. On an adjusted basis, it reported 58 cents a share, or $179.9 million, vs. 47 cents a share, or $144.8 million, in the 2006 period.

Analysts surveyed by Thomson Financial were expecting 58 cents a share on revenue of $960 million, but Allergan reported revenue of $993.7 million, compared to $806.8 million in the year-ago period. Total product net sales increased 23.6%, or 20.9% at constant currency, compared to the third quarter of 2006. Specialty pharmaceutical sales increased 16%, and core medical devices net sales increased 66% from the 2006 period.

Within the specialty pharmaceutical sales category, Botox sales increased 24.8% to $296.7 million. Within the medical device category, breast aesthetics increased 84%, to $217.8 million, obesity intervention increased 110.9% to $195.9 million, and facial aesthetics increased 329.1% to $141.6 million.

Looking ahead, the company updated its fourth-quarter and full-year guidance to reflect the $370 million acquisition of Esprit Pharma. Allergan expects between 56 cents and 57 cents a share in the fourth quarter and adjusted diluted earnings between $2.14 and $2.15 a share for the year, assuming a 4-cent per-share dilution from the Esprit acquisition. The Thomson Financial consensus target is for 57 cents a share in the fourth quarter and $2.15 for the year.

Also on Tuesday, Stiefel Laboratories said it entered into an agreement with Allergan to develop and market new products involving Tazarotene worldwide for dermatological use and to co-promote Tazorac, for mild to severe facial acne, in the U.S. Financial terms weren't disclosed.

Shares rose 33 cents, or 0.5%, to $67.36 in recent trading.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AGN $320.26 2.84%
AAPL $118.03 -0.71%
FB $105.41 -0.31%
GOOG $748.15 -0.02%
TSLA $229.64 5.22%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs